December 8, 2025Blood

Identifying biological differences between two clinical risk groups of cutaneous CD30+ T cell lymphoproliferative disorders

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective analysis identifies gene expression and mutation differences in CD30+ T LPD risk groups, suggesting distinct pathogenic pathways.

Median overall survival was 24.44 years for low risk and 7.21 years for adverse risk groups in cutaneous CD30+ T LPD.
Gene alterations in pathways involving epigenetics and signaling were found, with KDR and TET2 frequently mutated.
This observational analysis combined clinical, molecular, and pathologic data from diverse institutions across 22 years.
High-risk disease showed elevated MYC-driven programs and increased immune activation, highlighting critical therapeutic targets.

Cheng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis identifies gene expression and mutation differences in CD30+ T LPD risk groups, suggesting distinct pathogenic pathways.

Median overall survival was 24.44 years for low risk and 7.21 years for adverse risk groups in cutaneous CD30+ T LPD.
Gene alterations in pathways involving epigenetics and signaling were found, with KDR and TET2 frequently mutated.
This observational analysis combined clinical, molecular, and pathologic data from diverse institutions across 22 years.
High-risk disease showed elevated MYC-driven programs and increased immune activation, highlighting critical therapeutic targets.

Cheng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark